Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Result of AGM

1st Jul 2025 07:00

RNS Number : 0883P
Trellus Health PLC
01 July 2025
 

Trellus Health plc

("Trellus Health", the "Company" or the "Group")

 

Result of Annual General Meeting

 

The Annual General Meeting of Trellus Health plc was held at Temple Chambers, 3-7 Temple Avenue, London, EC4Y 0DT on 30 June 2025 at 1:00 p.m. (UK time)

 

All 13 resolutions put to members were passed on a poll. Resolutions 1 to 11 were passed as ordinary resolutions and resolutions 12 and 13 were passed as special resolutions. The full text of the resolutions passed at the Annual General Meeting is set out in the Notice of Meeting, which is available on the Company's website at https://trellushealth.com/investors

 

The number of votes cast for and against each of the resolutions proposed, and the number of votes withheld were as follows:

 

 Resolution

Votes for

%

Votes against

%

Votes withheld

Resolution 1 (Ordinary)

 

27,025,398

99.9999

29

0.0001

643,426

Resolution 2 (Ordinary)

 

20,516,614

75.92

6,508,690

24.08

643,549

Resolution 3 (Ordinary)

 

26,767,828

99.92

20,253

0.08

880,772

Resolution 4 (Ordinary)

 

26,290,923

97.87

571,760

2.13

806,170

Resolution 5 (Ordinary)

 

26,766,798

99.64

95,762

0.36

806,293

Resolution 6 (Ordinary)

 

26,756,319

99.60

106,364

0.40

806,170

Resolution 7 (Ordinary)

 

20,506,319

76.34

6,356,364

23.66

806,170

Resolution 8 (Ordinary)

 

19,851,366

73.90

7,011,317

26.10

806,170

Resolution 9 (Ordinary)

 

26,942,921

99.69

82,506

0.31

643,426

Resolution 10 (Ordinary)

 

26,948,536

99.72

76,891

0.28

643,426

Resolution 11 (Ordinary)

 

26,767,808

99.67

89,875

0.33

811,170

Resolution 12 (Special)

 

26,756,053

99.71

77,649

0.29

835,151

Resolution 13 (Special)

 

26,771,655

99.66

90,905

0.34

806,293

 

The Board notes that Resolutions 2, 7 and 8 received a significant number of votes against those resolutions. In accordance with the QCA Corporate Governance Code, the Board remains committed to maintaining an open and transparent dialogue with shareholders and will continue to consult on any material issues of concern.

 

As at 30 June 2025, there were 161,508,333 ordinary shares in issue. Shareholders are entitled to one vote per share. Votes withheld are not votes in law and so have not been included in the calculation of the proportion of votes for and against a resolution.

 

The full text of each resolution is available in the Notice of Annual General Meeting, published on our website.

Enquiries:

 

Trellus Health plc

 https://trellushealth.com/

Dr. Marla Dubinsky, Chief Executive Officer and Co-Founder

Via Walbrook PR

Joy Bessenger, Chief Financial Officer

Singer Capital Markets

 

Jen Boorer / James Todd / Jalini Kalaravy

Tel: +44 (0)20 7496 3000

Walbrook PR

Tel: +44 (0)20 7933 8780 or [email protected]

Paul McManus / Lianne Applegarth /

Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303/

Alice Woodings

+44 (0)7407 804 654

 

About Trellus Health plc (www.trellushealth.com)

Trellus Health® (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes.

 

Trellus Health integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate®, a whole-person technology-enhanced condition management platform. The Company is initially focusing on chronic costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying Trellus Elevate resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health struggles associated with a variety of chronic conditions, Trellus Health considers its approach to have potential utility and demand across many conditions.

 

Trellus Health also offers a seamless solution for pharmaceutical partners from clinical trials to commercialisation, harnessing resilience-based methods to drive both trial and patient support success by empowering patients to stay engaged, adhere to their treatment, and manage their health confidently.

 

The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD and Laurie Keefer, PhD, both world-leading experts at treating and healing both the physical and emotional impacts of IBD and have been innovators for whole-person healthcare for a combined 50 years.

 

Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information, visit: www.trellushealth.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGURSRRVKUNOUR

Related Shares:

Trellus Health.
FTSE 100 Latest
Value8,760.13
Change-25.20